ABVC BioPharma Selects Additional Vitargus® Phase II Study Sites
05 janv. 2022 08h30 HE
|
ABVC BioPharma, Inc.
Thailand Sites Join Australian Sites Confirmed to Participate in the Study Fremont, CA, Jan. 05, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage...
ABVC BioPharma’s Vitreous Substitute Vitargus Presented at 14th APVRS Congress
22 déc. 2021 08h30 HE
|
ABVC BioPharma, Inc.
Fremont, CA, Dec. 22, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...
ABVC BioPharma Medical Device Vitargus Receives Taiwan National Innovation Award
15 déc. 2021 08h30 HE
|
ABVC BioPharma, Inc.
Fremont, CA, Dec. 15, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...
ABVC BioPharma Introduces Dietary Supplement Based on Maitake Mushroom, Enters into $3.0 Million Distribution Agreement
09 déc. 2021 08h30 HE
|
ABVC BioPharma, Inc.
Fremont, CA, Dec. 09, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...
ABVC Biopharma Reports Third Quarter 2021 Financial and Operational Results
15 nov. 2021 16h33 HE
|
ABVC BioPharma, Inc.
FREMONT, CA, Nov. 15, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (Nasdaq: ABVC), a biotechnology company specializing in botanically based solutions that deliver high efficacy...
ABVC Biopharma Receives Additional $4,245,000 from Exercise of Warrants, Total Capital from Public Offering Increases to Approx. $11.1M
11 nov. 2021 09h00 HE
|
ABVC BioPharma, Inc.
FREMONT, CA, Nov. 11, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc.(Nasdaq: ABVC), a biotechnology company specializing in botanically based solutions that deliver high efficacy...
Central IRB Approved for ABV-1505 Phase II Part II in Taiwan Sites
27 oct. 2021 08h30 HE
|
ABVC BioPharma, Inc.
ABVC BioPharma Receives Taiwan Regulatory Approval for ABV-1505 ADHD Phase II Part 2 Clinical Study Completion of the Study Expected by the End of 2022 FREMONT, CA, Oct. 27, 2021 (GLOBE...
ABVC BioPharma Restructures Joint Venture to Expand Access to Early-Stage Research
12 oct. 2021 08h30 HE
|
ABVC BioPharma, Inc.
Restructured Venture Also Seeks Licensing Partners for ABVC FREMONT, CA, Oct. 12, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical...
ABVC BioPharma Completes Site Selection for ABV-1505 ADHD Phase II Part 2 Clinical Study
13 sept. 2021 08h30 HE
|
ABVC BioPharma, Inc.
Completion of the Study Expected by the End of 2022 FREMONT, CA, Sept. 13, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical...
ABVC BioPharma Announces New PCT Filings for MDD and ADHD Treatments
01 sept. 2021 08h30 HE
|
ABVC BioPharma, Inc.
FREMONT, CA, Sept. 01, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...